Table III.

Univariate analyses of the association of prognosis with clinicopathological parameters and CD44 expression in patients with renal cell carcinoma.

Variables	HR	95% CI	P-value
Recurrence-free survival
Age (>70/≤70 years)	1.908	0.686–5.302	0.215
Gender (male/female)	2.333	0.680–8.009	0.178
ECOG PS (≥1/0)	0.873	0.355–2.149	0.768
Tumor size (>10/≤10 cm)	3.405	0.990–11.714	0.052
Pathologic T stage (T2–3/T1)	2.430	0.875–6.750	0.088
Fuhrman nuclear grade (G3–4/G1–2)	3.433	1.350–8.727	0.010
CD44 expression (high/low)	9.669	3.869–24.162	<0.001
Disease-specific survival
Age (>70/≤70 years)	3.571	1.165–10.947	0.026
Gender (male/female)	4.928	0.641–37.908	0.125
ECOG PS (≥1/0)	0.911	0.306–2.710	0.867
Tumor size (>10/≤10 cm)	2.995	0.663–13.520	0.154
Pathologic T stage (T2–3/T1)	2.855	0.785–10.377	0.111
Fuhrman nuclear grade (G3–4/G1–2)	4.683	1.572–13.954	0.006
CD44 expression (high/low)	10.421	3.393–32.002	<0.001
Overall survival
Age (>70/≤70 years)	2.925	1.178–7.265	0.021
Gender (male/female)	1.328	0.487–3.627	0.579
ECOG PS (≥1/0)	0.855	0.363–2.012	0.719
Tumor size (>10/≤10 cm)	1.754	0.408–7.535	0.450
Pathologic T stage (T2–3/T1)	1.720	0.694–4.262	0.242
Fuhrman nuclear grade (G3–4/G1–2)	2.767	1.115–6.863	0.028
CD44 expression (high/low)	5.509	2.274–13.348	<0.001

HR, hazard ratio; CI, confidence interval. ECOG, Eastern Cooperative Oncology Group; PS, performance status.